Abstract:

Globally, the most common cancer to be diagnosed in women is breast cancer, surpassing lung cancer. One of the treatments used is carboplatin, which is a platinum-based drug. These substances function by preventing the growth of cancerous cells. We conducted a study to evaluate the dosage dependency of carboplatin in light of the adverse effects that have been recorded in patients. After being cultivated, the MTT test was used to determine the vitality of the MCF-7 breast cancer cell line. Afterwards, cDNA synthesis was carried out after RNA isolation using the TRIzol technique. Finally, a quantitative real-time polymerase chain reaction was used to analyze gene expression. Every single result was statistically examined using SPSS. The results demonstrated that MCF-7 cell lines multiplied both before and following carboplatin therapy. Furthermore, they showed that the STAT3 gene was expressed in MCF-7 both before and during the carboplatin treatment. According to our research, if carboplatin is taken at the lowest risk dosage, it can be very beneficial in treating breast cancer. However, since this is just an early study, more investigation and pre-clinical approval are required.

References:

[1] Ye, F., Dewanjee, S., Li, Y., Jha, N. K., Chen, Z. S., Kumar, A., et al., Advancements in clinical aspects of targeted therapy and immunotherapy in breast cancer. Mol Cancer. 2023 Jul 6;22(1):105.

[2] Arnold, M., Morgan, E., Rumgay, H., Mafra, A., Singh, D., Laversanne, M., et al. Current and future burden of breast cancer: Global statistics for 2020 and 2040. Breast. 2022 Dec;66:15–23.

[3] Pillai, D., Narayan, J., Gentry-Maharaj, A., Deo, S., Vijaykumar, D. K., Mukherjee, P., et al., Co-Creation of Breast Cancer Risk Communication Tools and an Assessment of Risk Factor Awareness: A Qualitative Study of Patients and the Public in India. Cancers (Basel). 2023 May 30;15(11):2973.

[4] Feng, Y., Spezia, M., Huang, S., Yuan, C., Zeng, Z., Zhang, L., et al., Breast cancer development and progression: Risk factors, cancer stem cells, signaling pathways, genomics, and molecular pathogenesis. Genes Dis. 2018 Jun;5(2):77–106.

[5] Yang, F., He, Q., Dai, X., Zhang, X., Song, D., The potential role of nanomedicine in the treatment of breast cancer to overcome the obstacles of current therapies. Front Pharmacol. 2023 Feb 22;14.

[6] McCrudden, C. M., McCarthy, H. O., Current status of gene therapy for breast cancer: progress and challenges. Appl Clin Genet. 2014;7:209–20.

[7] Ibnat, N., Chowdhury, E. H., Retarding breast tumor growth with nanoparticle-facilitated intravenous delivery of BRCA1 and BRCA2 tumor suppressor genes. Sci Rep. 2023 Jan 11;13(1):536.

[8] Karjoo, Z., Chen, X., Hatefi, A., Progress and problems with the use of suicide genes for targeted cancer therapy. Adv Drug Deliv Rev. 2016 Apr 1;99(Pt A):113–28.

[9] Mehrotra, R., Yadav, K., Breast cancer in India: Present scenario and the challenges ahead. World J Clin Oncol. 2022 Mar 24;13(3):209–18.

[10] Javanbakht, M., Tahmasebzadeh, S., Cegolon, L., Gholami, N., Kashaki, M., Nikoueinejad, H., et al., Oncolytic viruses: A novel treatment strategy for breast cancer. Genes Dis. 2023 Mar;10(2):430–46.

[11] Schmidt, M., Heimes, A. S., Immunomodulating Therapies in Breast Cancer—From Prognosis to Clinical Practice. Cancers (Basel). 2021 Sep 29;13(19):4883.

[12] Mustafa, G., Hassan, D., Ruiz-Pulido, G., Pourmadadi, M., Eshaghi, M. M., Behzadmehr, R., et al. Nanoscale drug delivery systems for cancer therapy using paclitaxel— A review of challenges and latest progressions. J Drug Deliv Sci Technol. 2023 Jun;84:104494.

[13] Dasari, S., Bernard Tchounwou, P., Cisplatin in cancer therapy: Molecular mechanisms of action. Eur J Pharmacol. 2014 Oct;740:364–78.

[14] Loh, C. Y., Arya, A., Naema, A. F., Wong, W. F., Sethi, G., Looi, C. Y., Signal Transducer and Activator of Transcription (STATs) Proteins in Cancer and Inflammation: Functions and Therapeutic Implication. Front Oncol. 2019 Feb 21;9.

[15] Tolomeo, M., Cascio, A., The Multifaced Role of STAT3 in Cancer and Its Implication for Anticancer Therapy. Int J Mol Sci. 2021 Jan 9;22(2):603.

[16] Carpenter, R., Lo, H. W., STAT3 Target Genes Relevant to Human Cancers. Cancers (Basel). 2014 Apr 16;6(2):897–925.

[17] Yu, K. D., Ye, F. G., He, M., Fan, L., Ma, D., Mo, M., et al. Effect of Adjuvant Paclitaxel and Carboplatin on Survival in Women With Triple-Negative Breast Cancer. JAMA Oncol. 2020 Sep 1;6(9):1390.

[18] Perez, E. A., Carboplatin in Combination Therapy for Metastatic Breast Cancer. Oncologist. 2004 Sep 1;9(5):518–27.